SCHEMBL3759286

SCHEMBL3759286

Nc1ccc(Nc2cnnc3ccccc23)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 3/20 0.53
MAPT P10636 3/20 0.47
TP53 P04637 2/20 0.47
ALOX15 P16050 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
KDM4E B2RXH2 1/20 0.47
APP P05067 1/20 0.47
HPGD P15428 1/20 0.47
SNCA P37840 1/20 0.47
BLM P54132 1/20 0.47
HSD17B10 Q99714 1/20 0.47
DNMT1 P26358 1/20 0.47
ALDH1A1 P00352 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
HTT P42858 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
ALOX12 P18054 1/20 0.44
CYP2C19 P33261 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1116308 0.86 KDM1A (0.48) KDM1AMAPTTP53ALOX15SMN1; SMN2
SCHEMBL10000202 0.83 ERBB2 (0.58) KDM1AMAPTKDM4EL3MBTL1HTT
SCHEMBL3764035 0.78 KMT2A (0.58) KDM1AMAPTSMN1; SMN2KDM4EHSD17B10
SCHEMBL18879049 0.75 GPR3 (0.44) KDM1AMAPTTP53SMN1; SMN2KDM4E
SCHEMBL20265361 0.75 ALDH1A1 (0.47) MAPTTP53SMN1; SMN2KDM4EHPGD
SCHEMBL4813919 0.75 DNMT1 (0.73) KDM1ADNMT1HTTAURKAAURKB
SCHEMBL1116019 0.74 EGFR (0.63) EGFR
SCHEMBL4739613 0.74 FADS1 (0.63) MAPTALOX15SMN1; SMN2KDM4EHPGD
SCHEMBL13056988 0.74 ABCG2 (0.55) MAPTTP53MEN1KMT2AEGFR
SCHEMBL3757886 0.73 MEN1 (0.68) KDM1AMAPTALDH1A1L3MBTL1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842805-B2 Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof MYREXIS, INC. (US) 2010-11-30 US disclosed
US-20080020985-A1 PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF MYRIAD GENETICS, INC. (US) 2008-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080020985-A1 PHARMACEUTICAL COMPOUNDS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF CASP3, CASP2, CASP5 KDM1A 3124/4885MAPT 2963/4885TP53 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.